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The pharmacodynamics of oxytetracycline was determined for pig respiratory
tract pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida.
Indices of potency were determined for the following: (i) two matrices, broth
and pig serum; (ii) five overlapping sets of twofold dilutions; and (iii) a high
strength starting culture. For A. pleuropneumoniae, minimum inhibitory con-
centration (MIC) was similar for the two matrices, but for P. multocida, differ-
ences were marked and significantly different. MIC and minimum
bactericidal concentration (MBC) serum: broth ratios for A. pleuropneumoniae
were 0.83:1 and 1.22:1, respectively, and corresponding values for P. multo-
cida were 22.0:1 and 7.34:1. For mutant prevention concentration (MPC)
serum: broth ratios were 0.79:1 (A. pleuropneumoniae) and 20.9:1 (P. multo-
cida). These ratios were corrected for serum protein binding to yield fraction
unbound (fu) serum: broth MIC ratios of 0.24:1 (A. pleuropneumoniae) and
6.30:1 (P. multocida). Corresponding fu serum: broth ratios for MPC were
almost identical, 0.23:1 and 6.08:1. These corrections for protein binding
did not account for potency differences between serum and broth for either
species; based on fu serum MICs, potency in serum was approximately four-
fold greater than predicted for A. pleuropneumoniae and sixfold smaller than
predicted for P. multocida. For both broth and serum and both bacterial spe-
cies, MICs were also dependent on initial inoculum strength. The killing
action of oxytetracycline had the characteristics of codependency for both
A. pleuropneumoniae and P. multocida in both growth media. The in vitro
potency of oxytetracycline in pig serum is likely to be closer to the in vivo
plasma/serum concentration required for efficacy than potency estimated in
broths.
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INTRODUCTION
The tetracycline group of antibiotics, which includes oxytetra-
cycline and doxycycline, has consistently had the highest vet-
erinary sales volume in the United Kingdom of the seven
antimicrobial drug classes analysed by Veterinary Antimicro-
bial Resistance and Sales Surveillance (UK-VARSS). They pos-
sess a broad spectrum of activity. However, resistance to drugs
of this group is common. For example, de Jong et al. (2014)
reported that, for pig isolates, 22% of Pasteurella multocida,
15% of Actinobacillus pleuropneumoniae and 82% of Streptococcus
suis were classified as resistant to tetracycline.
Oxytetracycline has been in extensive veterinary use, for
more than 60 years, in farm animal medicine. Although usu-
ally classified as a bacteriostat, in vitro studies have demon-
strated bactericidal actions for pneumonia pathogens
(Brentnall et al., 2012; Lees et al., 2016). In this in vitro study,
antimicrobial potency and efficacy of oxytetracycline against
two pathogenic species, implicated in pig pneumonia, P. multo-
cida and A. pleuropneumoniae, were investigated. The indices
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measured were as follows: (i) minimum inhibitory concentra-
tion (MIC), the lowest in vitro concentration which inhibits vis-
ible growth; (ii) minimum bactericidal concentration (MBC),
the concentration which produces a 3 log10 reduction in bacte-
rial count; (iii) mutant prevention concentration (MPC), the
concentration preventing the growth of the least susceptible
cells in high-density bacterial populations (Blondeau et al.,
2004); and (iv) time–kill curves quantifying the time course of
growth inhibition.
The European Union Committee on Antimicrobial Sensitivity
Testing (EUCAST) and the Clinical Laboratory Standards Insti-
tute (CLSI) have defined the internationally accepted methods,
standards and guidelines for MIC and MBC determinations.
Such standardization is essential when comparing data from
several laboratories, between countries and across time periods.
Moreover, it establishes cut-off values for antimicrobial sensitiv-
ity testing (Papich, 2013). These bodies require twofold dilu-
tions for MIC determinations, and this is important because,
when plotted on a histogram using a log-base 2 distribution,
the distributions are log-normal. These histograms are there-
fore readily examined for the purpose of identifying wild-type
distributions. The CLSI and EUCAST standards thus enable
determination of ECOFF and cut-offs for wild-type organisms.
For the purposes of this study, the standardized CLSI/
EUCAST methods of determining MIC and MBC have two dis-
advantages. As they are based on twofold dilutions, there is
potential for up to 100% error on single isolate estimates, thus
having a limitation regarding accuracy for each isolate. From
pharmacological and therapeutic dose determination perspec-
tives, it is accuracy and not precision that is the key objective.
To meet, in part, this concern on accuracy, previous studies in
this laboratory have used five sets of overlapping twofold dilu-
tions to reduce inaccuracy from approaching 100% to not
more than 20% (Aliabadi & Lees, 2001; Sidhu et al., 2010).
Secondly, the internationally recommended CLSI/EUCAST stan-
dards are based on the use of artificial growth media, such as
cation-adjusted Mueller–Hinton broth (CAMHB). Whilst these
provide optimal growth conditions in vitro, they differ in com-
position (chemically and immunologically) from biological flu-
ids and therefore may not be representative of bacterial growth
conditions in vivo. To provide comparisons between broth and
biological fluid growth matrices, and to establish possible differ-
ences between them, previous MIC, MBC and time–kill studies
in our laboratory have been undertaken in calf serum and
inflammatory exudate (Aliabadi & Lees, 2001, 2002; Sidhu
et al., 2010).
For some drug classes, differences between artificial broths
and biological fluids for determining antimicrobial drug
potency and efficacy are small, and unlikely to have a major
impact on dose determination, provided the nonprotein bound
serum drug concentration is used, as the protein bound frac-
tion is microbiologically inactive (Gonzalez et al., 2013; Tou-
tain et al., 2016). For other drug classes, differences between
broths and biological fluids may be large. Brentnall et al.
(2012) reported for a calf isolate of Mannheimia haemolytica an
oxytetracycline MIC in serum 19 times greater than the broth
MIC. In contrast, Illambas et al. (2009) and Toutain et al.
(2016) reported MICs some 50-fold smaller in calf serum com-
pared to broth for tulathromycin for M. haemolytica and
P. multocida calf isolates. Hence, the quantitative determination
of pharmacodynamic indices with improved accuracy and in
biological fluid matrices should be regarded, for some drug
classes, as appropriate and even necessary for determination of
PK/PD break points and the application of PK/PD principles to
dose determination. Furthermore, Zeitlinger et al. (2004) com-
mented ‘investigations without determination of protein bind-
ing must be considered highly speculative. . ...bacteria with
appropriate and well-defined growth in the selected medium
should be employed. . ..in order to be able to extrapolate data
from various models to in vivo situations, models should
always attempt to mimic physiological conditions as closely as
possible’.
A third consideration, in respect of optimizing clinical effi-
cacy and minimizing the emergence of resistance to antimicro-
bial drugs, is dosage in relation to pathogen load. For
prophylaxis, metaphylaxis and treatment early in the course of
disease, when the pathogen load is low or absent, many drugs
will, at recommended dosages, either prevent or cure disease,
in concert with natural body defences. The major challenge,
however, is to achieve a bacteriological cure when pathogen
density in the biophase is high. For this reason, in this study, a
high starting inoculum count of approximately 107 CFU/mL
was selected, in preference to the inoculum count of
5 9 105 CFU/mL recommended in CLSI and EUCAST guideli-
nes for MIC and related studies.
The aims of this investigation were as follows: (i) to deter-
mine the degree of protein binding of oxytetracycline in pig
serum; (ii) for oxytetracycline against six isolates each of
A. pleuropneumoniae and P. multocida (known respiratory patho-
gens in the pig) (a) to determine MICs using five sets of over-
lapping twofold dilutions, (b) to compare MICs, MBCs and
MPCs of oxytetracycline in two matrices, artificial broth and
pig serum, (c) to establish time–kill curves in both growth
matrices for eight multiples of MIC, using high starting inocu-
lum counts; (iii) for two isolates each of P. multocida and
A. pleuropneumoniae to investigate the effect on MIC of (a) vary-
ing the initial inoculum pH over the range 7.0–8.0, (b)
increasing the calcium and magnesium concentrations of
CAMHB; and (iv) for six isolates each of P. multocida and
A. pleuropneumoniae to determine MICs using low, intermediate
and high starting inoculum counts.
MATERIALS AND METHODS
Serum protein binding of oxytetracycline
A high-pressure liquid chromatography (HPLC) method with
ultraviolet (UV) detection was used to quantify oxytetracycline
concentrations in pig serum (Horspool & McKellar, 1990). The
HPLC system comprised a Dionex Ultimate 3000 pump and
autosampler, connected to a Dionex UVD340S detector
(Thermo Fisher UK Ltd., Boundary Way, Hemel Hempstead,
© 2017 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd.
2 L. Dorey et al.
UK). UV detection was set to wavelength 354 nm, and the
retention time of oxytetracycline was 4 min. Chromatographic
data were analysed using Chromeleon version 6.80, and con-
centrations of oxytetracycline were calculated using ratios of
peak area, compared to the internal standard. Recovery of the
drug was determined by comparing the peak area of standards
in methanol and standards in serum, when known oxytetracy-
cline concentrations were spiked into methanol and serum,
respectively. The spiking concentrations were 0, 0.1, 0.25, 0.5,
1, 2.5, 5, 10 and 25 lg/mL.
Two sample sets were used as follows: (i) spiked oxytetracy-
cline standards in serum to provide the total concentration of
protein bound and free drug and (ii) serum samples prepared
as in (i) then filtered using ultrafiltration devices (Amicon Ultra
Centrifugal filters, Ultracel 10 k, Sigma-Aldrich Company Ltd.,
Dorset, UK). Briefly, a 3-mL aliquot was placed in the ultrafilter
unit and centrifuged at 4000 g for 20 min at 25 °C. The
ultrafiltrate was assayed for drug concentration to estimate
oxytetracycline concentration in the protein free fraction. For
each concentration, unbound concentration was determined
for three serum samples.
Origin, storage and selection of bacterial isolates
Twenty isolates of P. multocida were supplied by Don Whitley
Scientific, Shipley, West Yorkshire, UK. They also supplied
three ATCC reference strains, A. pleuropneumoniae ATCC
27090, Enterococcus faecalis ATCC 29212 and Escherichia coli
ATCC 25922 to validate MIC determinations. Eight isolates of
A. pleuropneumoniae were supplied by A. Rycroft (Royal Veteri-
nary College, Hawkshead Campus, Hatfield, Herts., UK). All
P. multocida and A. pleuropneumoniae isolates were derived from
EU field cases of pig pneumonia. They were stored in 10%
Marvel milk powder, 15% glycerol and sterile distilled H2O to
100% at 80 °C. The mixture was sterilized by boiling for
5 sec, allowed to cool for 12 h and then boiled again for a fur-
ther 5 sec.
Based on three criteria, six isolates of each species were
selected: (i) ability to grow logarithmically in both broth and
pig serum, (ii) susceptibility to oxytetracycline in disc diffusion
assays (data not shown), and (iii) the highest and lowest broth
MICs and four isolates with intermediate MICs, determined
using twofold dilutions (data not shown). This initial selection
procedure ensured that all isolates could be used in subsequent
investigations in both growth media and that they comprised a
small but diverse range of susceptible isolates.
Culture methods and bacterial counts
For A. pleuropneumoniae, chocolate Mueller–Hinton agar
(CMHA) was used to grow the organism on a solid medium
and Columbia broth supplemented with 2 lg/mL nicotinamide
adenine dinucleotide (NAD) was used as the liquid broth. CLSI
guidelines require use of Veterinary Fastidious Medium for the
liquid culture of A. pleuropneumoniae. However, for isolates used
in this study, MIC end point was more readily and reliably
established using Columbia broth. Mueller–Hinton agar supple-
mented with 5% defibrinated sheep blood (MHA) was used to
grow P. multocida. The liquid medium used for P. multocida
was CAMHB. They were incubated in a static incubator at
37 °C for 18–24 h.
Bacterial counts were determined by serial dilution and spot
plate counts. Tenfold or 100-fold dilutions were made in phos-
phate-buffered saline. Three 10 lL drops of the appropriate
dilutions were dropped onto the agar surface and allowed to
dry for 10 min prior to incubating. After 24-h incubation, the
mean colony-forming unit (CFU) count for each 10 lL was
determined and multiplied by 100 to give the CFU/mL and
then multiplied by the dilution factor to obtain the starting
count.
Minimum inhibitory and minimum bactericidal concentrations
MICs and MBCs were determined by microdilution for six iso-
lates each of A. pleuropneumoniae and P. multocida, based on
CLSI guidelines (2008) and using CLSI recommended broth
(for P. multocida but not for A. pleuropneumoniae). In addition,
MICs were determined in 100% pig serum. For both growth
media, five overlapping sets of twofold serial dilutions of oxyte-
tracycline were prepared, with a large initial range from lowest
set of 0.0078 to 128 lg/mL and highest set of 0.014 to
230 lg/mL in 96-well plates. Bacterial cultures were grown in
broth or serum to 0.5 McFarland Standard, corresponding to
approximately 1–2 9 108 CFU/mL. This was diluted tenfold to
obtain the intended starting inoculum, 1–2 9 107 CFU/mL,
which is higher than CLSI recommendation of 5 9 105 CFU/
mL. The higher inoculum count was deliberately selected, to
be equivalent to a medium to heavy clinical challenge and to
facilitate comparison with in vitro time–kill curves (vide infra).
Oxytetracycline solutions, media and bacterial cultures were
added to each cell based on the concentration/volume formula,
C1V1 = C2V2; that is for a concentration of 2 lg/mL oxytetra-
cycline, the following were added to the well: 4 lL of 100
lg/mL oxytetracycline stock solution added to 194 lL of broth
or serum and then 2 lL of culture. The plate was sealed and
incubated statically for 24 h at 37 °C. Spot plate counts were
prepared immediately after plate inoculation.
Each test with each isolate was repeated in triplicate for con-
firmation and validation. Growth was indicated by turbidity or
appearance of a growth spot, and the MIC was the lowest con-
centration which inhibited visible growth. ATCC reference
strains (vide supra) were used in all assays, but the starting
counts were 1.105 CFU/ml, as required by CLSI methods. The
positive control well contained medium and pathogen and was
expected to yield a positive growth result; the negative control
well contained medium and oxytetracycline and was expected
to yield no growth; and the blank control contained medium
only and was expected to achieve no growth. If results were
not within the expected range, the test was repeated.
MBCs were determined in accordance with CLSI standards
(2008). The 96 wells were-examined for growth to determine
the MIC and, in addition to that well, wells containing five
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subsequent concentrations higher than MIC were established
by spot plating. This indicated a 3 log10 reduction in inoculum
count.
Mutant prevention concentration
Fresh cultures were grown on agar, and approximately 100
single CFUs were collected, with a sterile dampened swab and
used to inoculate culture from plates into a volumetric flask
containing 200 mL of prewarmed broth. This was placed in a
static incubator overnight at 37 °C. The next day, 1 mL of cul-
ture was added to 9 mL broth and placed in an orbital incuba-
tor at 37 °C and 180 rpm for 4 h. After 4 h, the bacterial
suspension yields a theoretical count of 1–2 9 1011 CFU/mL.
A spot plate was used to confirm inoculum density. For P. mul-
tocida, as a rapidly growing pathogen, no centrifuge step was
required. However, for the more fastidious organism, A. pleu-
ropneumoniae, a centrifuge step was used when required. The
drug concentrations were 1, 2, 4, 8, 16, 32, 64 and 128 mul-
tiples of the MIC for each isolate. The concentration ranges
were narrowed down two further times; for example, if MPC
was 649 MIC, the next range would be 32, 36, 40, 44, 48,
52, 56, 60 and 649 MIC, and the final range if the MPC was
369 MIC would be 32, 32.5, 33, 33.5, 34, 34.5, 35, 35.5
and 369 MIC.
Oxytetracycline solution (0.5 mL) was applied to cold, dry
agar plates and left to dry; then, 100 lL of culture was added
to the plate and allowed to dry. Plates were incubated at 37 °C
for 72 h and checked for growth every 24 h. MPC was
recorded as the lowest oxytetracycline concentration that
inhibited bacterial growth completely after 72-h incubation.
The method was validated against that described by Blondeau
(2009). This provided full confidence in the current methodol-
ogy. For each of six isolates of each organism, triplicate mea-
surements were carried out, using both broth and serum as
growth matrices.
Antimicrobial growth (time–kill) curves
Two to three colonies of the test isolate were added to 5 mL
broth or serum and incubated overnight in an orbital incuba-
tor under standard conditions, as described above. Fifty micro-
litres of this culture was diluted 1:50 in prewarmed broth or
serum and incubated statically for 1 h at 37 °C to a 0.5
McFarland Standard. This was then diluted tenfold to obtain
the intended starting inoculum, to be consistent with MIC
determinations at 1–2 9 107 CFU/mL, and confirmed using
colony counts. Drug concentrations of eight multiples of MIC
(0.25, 0.5, 1, 1.5, 2, 4, 6 and 89 MIC) were prepared in pre-
warmed broth or serum. Ten microlitres of the prepared cul-
ture was used to inoculate the dilutions to yield a 1 mL final
volume. Fifty microlitres of each culture was sampled, and the
count was determined by serial dilution and spot plates at nine
times: 0, 0.25, 0.5, 0.75, 1, 2, 4, 8 and 24-h incubation. The
negative control contained no organism, whilst for the positive
control, no drug was added. Spot plates were examined for
contamination. Each test was repeated in triplicate for six iso-
lates of both organisms grown in both broth and serum. The
lower limit of quantification (LLOQ) was 33 CFU/mL.
Monitoring pH before and after MIC determination
The pH of serum was regularly monitored in all experiments,
as, after 24-h incubation, pH may change with the release of
products of bacterial metabolism. To quantify pH change from
start to end of incubation in MIC studies, the macrodilution
method was used. The MIC determinations were made in tripli-
cate in both broth and serum for two isolates each of P. multo-
cida and A. pleuropneumoniae.
Effect of pH on MIC
The initial pH of each medium, broth and serum, was adjusted
to values of 7.0, 7.2, 7.4, 7.6, 7.8 or 8.0 using hydrochloric
acid (HCl, 1 M) or sodium hydroxide (NaOH, 1 M) MICs were
determined by macrodilution and repeated in triplicate with
five overlapping sets of twofold dilutions as a preliminary study
for two isolates each of P. multocida and A. pleuropneumoniae.
Effect of cation adjustments on MIC
CLSI guidelines suggest the use of CAMHB for the culture of
P. multocida and the calcium and magnesium ion concentra-
tions of CAMHB, to meet CLSI standards, are in the ranges 20
–25 mg/L Ca++ and 10–12.5 mg/L Mg++. The concentrations
of these divalent cations were increased by 0, 5, 10, 15, 20,
25, 30 mg/L Ca++ by adding CaCl2 stock solution to 1 L
CAMHB and by 0, 3, 6, 10, 12, 15 and 18 mg/L Mg++ by
adding 10 mg/mL MgCl2 stock solution to 1 L CAMHB. MIC
determinations were repeated three times as a preliminary
study for two P. multocida and A. pleuropneumoniae isolates.
Actinobacillus pleuropneumoniae was investigated for compara-
tive purposes with P. multocida.
Effect of inoculum size on MIC
To determine the effect of initial inoculum size on MIC, three
initial inoculum strengths were evaluated as follows: high
(108 CFU/mL), intermediate (106 CFU/mL) and low (104
CFU/mL). To prepare the cultures, a 0.5 McFarland standard
was made; this has a theoretical value of 1.5 9 108 CFU/mL
(high). Two 1:10 dilutions provide a theoretical value of
1.5 9 106 CFU/mL (intermediate). A further two 1:10 dilu-
tions give a theoretical value of 1.5 9 104 CFU/mL (low).
MICs were determined in triplicate in broth and serum for six
isolates each of P. multocida and A. pleuropneumoniae, using five
overlapping sets of twofold dilutions.
Data collection and analysis
Data were recorded on Microsoft Excel and processed using
GraphPad Prism v6. The data were analysed using IBM SPSS
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Statistics 22 by Kruskal–Wallis H with post hoc Mann–Whitney
U-test.
RESULTS
Serum protein binding
The standard curve for concentrations of oxytetracycline in
serum was linear for eight concentrations over the range 0.1–
25 lg/mL. The intra-assay CV%s for three batches of serum
were 24.1, 18.5 and 15.2%. The mean (SD) percentage protein
binding for oxytetracycline in pig serum was 70.9 (9.19) and
was independent of total concentration.
Minimum inhibitory, minimum bactericidal and mutant prevention
concentrations
Figures 1–2 illustrate MIC and MBC for A. pleuropneumoniae
and P. multocida in broth and serum, indicating the interiso-
late variability and reproducibility with triplicate analyses per
isolate. Table 1 presents geometric means of MIC, MBC and
MPC in broth, serum and serum MIC corrected for drug bind-
ing to serum protein, that is fraction unbound (fu) serum
MIC. Table 2 indicates serum: broth and fu serum: broth
ratios for each of these indices and Table 3 presents the ratios
MBC: MIC and MPC: MIC for each growth matrix. For repeata-
bility, the coefficient of variation ranged from 5 to 11% for
P. multocida serum MIC and 2 to 24% for A. pleuropneumoniae
serum MIC.
For A. pleuropneumoniae, MICs were similar in serum and
broth; the geometric mean serum: broth ratio was 0.83:1.
The corresponding ratio for MBC was 1.22:1. These differ-
ences between serum and broth were not statistically signifi-
cant. However, after correcting for 71% serum protein
binding, the fu serum: broth MIC ratio for A. pleuropneumo-
niae was 0.24:1, indicating an approximately fourfold differ-
ence between experimental and predicted values of MIC
(P < 0.01).
For P. multocida, the uncorrected serum: broth ratios were
22.0:1 for MIC and 7.34:1 for MBC (P < 0.01 for both
indices). The fu serum: broth ratios were lower, 6.30:1 for
MIC (P < 0.01) and 2.14:1 for MBC (P < 0.05) indicating
greater than sixfold and twofold differences, respectively, after
correction for the microbiologically inactive protein bound
fraction.
For both A. pleuropneumoniae and P. multocida, MBC: MIC
ratios revealed both bacterial species and growth medium dif-
ferences. For A. pleuropneumoniae, the MBC: MIC ratio in
broth was 2.7:1 compared to 4.0:1 in serum, whereas for
P. multocida, corresponding ratios were, conversely, 7.7:1 and
2.6:1. Thus, comparing the two species, the MBC/MIC differ-
ence was greater for P. multocida in broth, whereas the
MBC/MIC difference was greater for A. pleuropneumoniae in
serum. The differences in MBC: MIC ratios between broth
and serum were statistically significant for both species
(P < 0.01).
For the determination of MPCs, a pilot test validated the
method used compared to that of Blondeau (2009) (data not
shown). Geometric mean MPCs and MPC: MIC ratios for six
isolates each of A. pleuropneumoniae and P. multocida are pre-
sented in Tables 1 and 3. Figure 3 illustrates the interisolate
variability of MPC in broth and serum, with triplicate analysis
for each isolate.
For A. pleuropneumoniae, MPCs exceeded MICs in both media,
17.7-fold in broth and 16.8-fold in serum; geometric mean
MPCs were 44.4 lg/mL (broth) and 35.1 lg/mL(serum). For
P. multocida, MPCs were 22.89 MIC in broth and 22.09 MIC
in serum; geometric mean MPCs were 6.84 lg/mL (broth) and
142.8 lg/mL (serum).
The MPC serum: broth ratio for A. pleuropneumoniae was
0.79:1, which was similar to the MIC serum: broth ratio of
0.83:1. The corresponding MPC serum: broth ratio for P. mul-
tocida was 20.9:1, which was almost identical to the serum:
broth MIC ratio of 22.0:1. After correcting serum MPCs for
Fig. 1. Individual isolate MICs and MBCs for oxytetracycline for Acti-
nobacillus pleuropneumoniae A21-A26 in broth (upper graph) and serum
(lower graph). Standard deviation bars indicate repeatability (n = 3 for
each isolate). [Colour figure can be viewed at wileyonlinelibrary.com].
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protein binding, the fu serum: broth MPC ratios were approxi-
mately fourfold lower (A. pleuropneumoniae) and sixfold higher
(P. multocida) than the predicted ratio of 1:1. These differences
were virtually identical to those obtained for MIC.
pH measurement before and after MIC determinations
The pH of broth increased from 7.10 to 7.28 and in serum the
pH increased from 7.27 and 7.40.
Effect of pH on MIC
The pH of the initial culture media (broth and serum) was
adjusted to 7.0, 7.2, 7.4, 7.6, 7.8 or 8.0. For both organisms,
broth MICs decreased (reflecting a potency increase) progres-
sively as pH became more alkaline, from pH 7.4 to 8.0. For
serum, MICs for both species were not significantly affected by
pH (Figs 4 & 5).
Effect of cation adjustments on MIC
Concentrations of the divalent cations, calcium and magne-
sium in broth were increased by 0, 5, 10, 15, 20, 25, 30 mg
Ca++/L and 0, 3, 6, 10, 12, 15 and 18 mg Mg++/L. These
alterations to calcium and magnesium concentrations did not
Table 1. Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida (PM) MIC, MBC and MPC for broth, serum and free concentration in serum
(fu serum)†
Organism Medium MIC MBC MPC
APP Broth 2.50 (0.70) 6.71 (0.43) 44.35 (12.63)
Serum 2.08 (0.43) 8.22 (0.95)* 35.09 (6.66)*
fu Serum 0.61 (0.13)** 2.39 (0.28)** 10.21**
PM Broth 0.30 (0.12) 2.28 (0.47) 6.84 (2.76)
Serum 6.48 (1.45)** 16.75 (2.04)** 142.84 (33.27)**
fu Serum 1.89 (0.42)** 4.87 (0.59)* 41.57**
†fu serum = serum concentrations corrected for protein binding. Geometric means (SD) of oxytetracycline concentrations for each of six isolates of
each organism determined in triplicate. Significant differences of serum and fu serum from broth values: *P < 0.05, **P < 0.01.
Table 2. Serum:broth and fu serum:broth ratios of MIC, MBC and MPC
for Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida (PM)
Organism Medium MIC MBC MPC
APP Serum:broth 0.83:1 1.22:1 0.79:1
fu Serum:broth 0.24:1 0.36:1 0.23:1
PM Serum:broth 21.96:1 7.34:1 20.89:1
fu Serum:broth 6.30:1 2.14:1 6.08:1
fu serum = serum concentrations corrected for protein binding. Ratios
for triplicate analyses for each of six isolates of each organism.
Table 3. MBC: MIC and MPC: MIC ratios for Actinobacillus pleuropneu-
moniae (APP) and Pasteurella multocida (PM) in broth and serum
Organism Medium MBC:MIC MPC:MIC
APP Broth 2.7:1 17.7:1
Serum 4.0:1 16.8:1
PM Broth 7.7:1 22.8:1
Serum 2.6:1 22.0:1
Ratios for triplicate analyses for each of six isolates of each organism.
Fig. 2. Individual isolate MICs and MBCs for oxytetracycline for Pas-
teurella multocida P1-P6 in broth (upper graph) and serum (lower
graph). Standard deviation bars indicate repeatability (n = 3 for each
isolate). Note differing ordinate scales. [Colour figure can be viewed at
wileyonlinelibrary.com].
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affect MIC for two isolates of P. multocida or A. pleuropneumo-
niae (Fig. 6).
Effect of inoculum size on MIC
MICs were determined in broth and serum for six isolates each of
P. multocida (Table 4) and A. pleuropneumoniae (Table 5) with
three initial inoculum strengths. MICs were inoculum size depen-
dent, increasing progressively with inoculum size. MIC ratios
high: low inocula were significant (P < 0.01) for broth and
serum for both organisms. Ratios high: medium inocula were also
significant for both media (P < 0.05). For P. multocida serum:
broth, MIC ratios were in the range 30:1 to 40:1 and the fu
serum: broth MIC range was 8.7:1 to 11.6:1. For A. pleuropneu-
moniae, serum: broth ratios were in the range 1.03:1 to 1.41:1
and ratios of fu serum: broth were in the range 0.30:1 to 0.41:1.
Time–kill curves
Time–kill curves for oxytetracycline are illustrated in Figs 7
(A. pleuropneumoniae) and 8 (P. multocida). For A. pleuropneumo-
niae, little growth inhibition occurred at concentrations <19
MIC, resulting in a 2–3 log10 increase in CFU/mL over 24 h at
0.25 and 0.59 MIC. At 1.59 MIC, there was a 1–2 log10
reduction in CFU/mL by 8 h in both media. At concentrations
exceeding 49 MIC, bactericidal activity occurred by 4 h, and
by 24 h, there was a 5 log10 CFU/mL decrease in both media.
For P. multocida, little growth inhibition occurred at concen-
trations less than MIC in both matrices. Progressively increasing
inhibition was obtained at 1.5, 2 and 49 MIC in broth, and bac-
tericidal activity occurred by 8 h at 69 MIC and 4 h at 89 MIC.
In serum, for 6 and 89 MIC, a 3 log10 decrease in CFU/mL was
obtained by 24 h. Despite a more rapid initial reduction in bac-
terial count in broth than in serum, by 24 h there was virtual
eradication (bacterial count <33 CFU/mL) at 6 and 89 MIC in
serum. The killing action of oxytetracycline was judged to be
codependent in both fluids for both micro-organisms.
DISCUSSION
Indices of oxytetracycline potency and growth medium
Determination of potency for antimicrobial drugs in broths, as
required by CLSI and EUCAST standards, has many
Fig. 3. Individual isolate broth and serum MPCs for oxytetracycline for
Actinobacillus pleuropneumoniae (upper graph) and Pasteurella multocida
(lower graph). Standard deviation bars indicate repeatability (n = 3 for
each isolate). Note differing ordinate scales for broth and serum for
P. multocida. [Colour figure can be viewed at wileyonlinelibrary.com]. Fig. 4. Pasteurella multocidaMICs for two isolates in broth and serum at
six initial pH values: lines of best fit and means. Standard deviation bars
indicate repeatability (n = 3) for each isolate). Note differing scales.
[Colour figure can be viewed at wileyonlinelibrary.com].
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advantages; their methods incorporate quality controls, break
points and epidemiological/wild-type cut-offs, which ensure
that MIC data are comparable between laboratories and across
countries. This is appropriate for routine antimicrobial suscepti-
bility testing. However, the present data suggest that serum
might be a more relevant fluid than broth for potency determi-
nation, when the objective is estimation of PK/PD break points
and prediction of a dose schedule for oxytetracycline for clini-
cal use in the pig, that is based on pharmacokinetic/pharmaco-
dynamic integration and modelling approaches.
However, CLSI/EUCAST methods of determining MIC and
MBC and the Blondeau (2009) described MPC method have
two disadvantages. First, being based on twofold dilutions,
there is potential for up to 100% error on single isolate esti-
mates, thus having a limitation regarding accuracy for individ-
ual isolates; this study used five sets of overlapping twofold
dilutions, reducing inaccuracy to no >20%. Second, the CLSI/
EUCAST standards are based on the use of growth media, such
as CAMHB, formulated to facilitate growth in vitro. Therefore,
Fig. 5. Actinobacillus pleuropneumoniae MICs for two isolates in broth
and serum at six initial pH values: lines of best fit and means. Standard
deviation bars indicate repeatability (n = 3) for each isolate). [Colour
figure can be viewed at wileyonlinelibrary.com].
Fig. 6. Mean and standard deviation broth (CAMHB) MICs (lg/mL) (for
triplicate determinations) for two isolates of Pasteurella multocida. Con-
centrations of calcium and magnesium were increased by additions to
MHB as follows: Group 1, 0 mg Ca++/L and 0 mg Mg++/L; Group 2,
5 mg Ca++/L and 3 mg Mg++/L; Group 3, 10 mg Ca++/L and 6 mg
Mg++/L; Group 4, 15 mg Ca++/L and 10 mg Mg++/L; Group 5, 20 mg
Ca++/L and 12 mg Mg++/L; Group 6, 25 mg Ca++/L and 15 mg
Mg++/L; and Group 7, 30 mg Ca++/L and 18 mg Mg++/L. [Colour
figure can be viewed at wileyonlinelibrary.com].
Table 4. Pasteurella multocida MICs for broth and serum with three
initial inoculum strengths†, ratios of MICs and serum:broth ratios
Inoculum size Broth MIC Serum MIC Serum:broth ratio
High 0.82 (0.22) 28.80 (0.00) 34.91:1
Medium 0.18 (0.01) 7.23 (0.00) 40.16:1
Low 0.14 (0.02) 4.14 (0.27) 30.06:1
High:medium ratio 4.6:1* 4.0:1*
High:low ratio 6.0:1** 7.0:1**
Medium:low ratio 1.3:1 1.7:1
†High (108 CFU/mL), medium (106 CFU/mL) and low (104 CFU/mL).
Geometric mean (SD) MICs: triplicate analyses for each of six isolates.
Significance of differences for high: medium, high: low and medium:
low inocula: *P < 0.05, **P < 0.01.
© 2017 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd.
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they differ in composition from biological fluids and hence may
not be fully representative of bacterial growth conditions
in vivo (Aliabadi & Lees, 2001, 2002; Nightingale and Mura-
kawa 2002; Zeitlinger et al., 2004; Zeitlinger et al., 2008;
Sidhu et al., 2010).
Differences between broths and biological fluids for determin-
ing drug potency, for some drug classes, are small and may
not have a significant impact on dose determination, provided
the nonprotein bound plasma/serum drug concentration is
known and applied. For other drug classes, however, differ-
ences between broths and biological fluids may be large. Fur-
ther refinement of the methodology used in this study would
be to determine potency not only in serum but also in the pres-
ence of other ‘natural’ constituents, such as leucocytes and
antibodies. Moreover, the time–kill studies were based on expo-
sure of the bacteria to fixed oxytetracycline concentrations for
a predefined time period. In vivo, concentrations in serum and
the biophase first increase and then decrease after systemic,
nonvascular dosing. Therefore, in vitro time–kill methods, such
as hollow fibre models, which better reflect the circumstances
of clinical exposure, could be used in future studies to better
simulate in vivo concentration–time profiles. Serum is a more
relevant fluid than broth first for MIC determination and time–
kill curves and then for PK/PD break point determination
because (i) broth is nonbiological and formulated to optimize
the growth of bacteria in vitro; (ii) for dose determination pur-
poses, accuracy (not precision) of MIC determination is the key
factor.
Variability between and within microbial species is a natural
phenomenon, resulting from environmental/evolutionary influ-
ences over time. For wild-type organisms of each species, there
is corresponding interstrain variability in the antimicrobial
drug potency indices, MIC, MBC and MPC for all drugs. In
Table 5. Actinobacillus pleuropneumoniae (APP) MICs for broth and
serum with three initial inoculum strengths†, ratios of MICs and
serum:broth ratios
Inoculum size Broth MIC Serum MIC Serum: Broth ratio
High 0.89 (0.22) 1.26 (0.00) 1.41:1
Medium 0.27 (0.16) 0.28 (0.08) 1.02:1
Low 0.13 (0.01) 0.14 (0.01) 1.03:1
High:medium ratio 3.3:1 4.5:1*
High:low ratio 6.7:1** 9.2:1**
Medium:low ratio 2.1:1 2.0:1
†High (108 CFU/mL), medium (106 CFU/mL) and low (104 CFU/mL).
Geometric mean (SD) MICs: triplicate analyses for each of six isolates.
Significance of differences for high: medium, high: low and medium:
low inocula: *P < 0.05, **P < 0.01.
Fig. 7. In vitro inhibition of growth of Actinobacillus pleuropneumoniae
over 24-h exposure to 8 multiples of MIC for oxytetracycline in (A)
Columbia broth supplemented with NAD and (B) serum (n = 6). Stan-
dard deviation bars shown. LLOQ was 33 CFU/mL. [Colour figure can
be viewed at wileyonlinelibrary.com].
Fig. 8. In vitro inhibition of growth of Pasteurella multocida over 24-h
exposure to 8 multiples of MIC for oxytetracycline in (A) CAMHB and
(B) serum (n = 6). Standard deviation bars shown. LLOQ was 33
CFU/mL. [Colour figure can be viewed at wileyonlinelibrary.com].
© 2017 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd.
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addition, the clinical use of antimicrobial drugs exerts selective
pressures on micro-organisms, potentially leading to reduced
susceptibility to their killing actions.
It has previously been demonstrated for oxytetracycline and
farm animal pathogens that growth medium can influence
MIC profoundly. Brentnall et al. (2012) compared
oxytetracycline MICs against an isolate of calf M. haemolytica
in five matrices, reporting values of 0.5, 0.8, 14.8, 12.8 and
11.2 lg/mL in MHB, CAMHB, calf serum, calf exudate and calf
transudate, respectively. A subsequent calf study from our labo-
ratory described similar (approximately 20-fold) MIC differences
for oxytetracycline in serum compared to MHB for six calf iso-
lates of M. haemolytica and P. multocida (Lees et al., 2016).
In another recent study, Honeyman et al. (2015) compared
several tetracyclines for MICs in broth and 50% broth: 50%
mouse serum. For a single strain of Streptococcus pneumoniae,
MICs were identical for the two media for five compounds but,
with added serum, twofold to fourfold increases were obtained
for five, whilst MIC was increased 32-fold for one compound.
For a strain of Staphylococcus aureus, however, MIC was
increased in the broth: serum combined matrix relative to pure
broth for all 12 compounds investigated, and for seven, the
increase was in the range eightfold to 128-fold. Moreover, for
the latter species, 50% human serum exerted a similar effect
quantitatively as mouse serum. Therefore, as in the present
investigation, the effect of serum on MIC was, for several drugs
of the tetracycline group, profound and bacterial species depen-
dent.
Factors potentially influencing oxytetracycline potency
The serum: broth MIC ratios obtained in this study were
0.83:1 for A. pleuropneumoniae and 22.0:1 for P. multocida.
Therefore, the serum/broth differences were markedly species
dependent, and these differences were confirmed by similar
serum: broth ratios for MBC and MPC for each species. Despite
these marked matrix-dependent differences in three inhibitory
concentrations, MIC, MBC and MPC, the time–kill curves for
broth and serum for each species were similar, when estab-
lished using multiples of MIC. The similarity between the time–
kill curves refers to the shape of the curve and consequential
effect (concentration, co-, or time-dependent) and not of the
concentrations required to elicit this effect. Therefore, we can
conclude that although the drug concentration required to pro-
duce these results has the same serum: broth ratio, the shape
of the curve and drug effect remains the same/similar.
The serum/broth differences in MIC, MBC and MPC were
bacterial species dependent, as strikingly illustrated by the data
for P. multocida. For this organism, correction for protein bind-
ing yielded a mean fu serum MIC of 1.89 lg/mL, whilst broth
MIC for the same isolates was 0.30 lg/mL. Thus, the fu serum
MIC was 6.3-fold greater than the broth MIC, the universally
accepted standard. For MPC, the difference between serum and
broth after correction for protein binding was 6.1-fold. This
indicates an inhibition of the killing action of oxytetracycline
by some serum factor(s). The cause requires further study by
methods for example repeating the test with protein free
serum.
For P. multocida, MIC differences between serum and broth
could be due to the natural buffers or differing composition of
serum compared to broth. The present findings indicate a small
effect of pH on activity in broth with greater potency (reduced
MIC) at alkaline pH. However, MIC was independent of pH in
serum. Other investigators have reported pH dependency of
broth MIC for tetracycline, penicillin, sulphonamides and
aminoglycosides; the pHs for optimal activity were 6.6, 6.8,
7.3 and 7.8, respectively (Garrod & Waterworth, 1969).
For A. pleuropneumoniae the MIC, MBC and MPC serum:broth
ratio ranges were 0.79–1.22:1, whereas for P. multocida, the
ratio range was 7–22:1. The causes to these bacterial species
differences are to be determined. Zeitlinger et al. (2008) com-
pared growth curves, in the absence of antimicrobial drugs, of
S. aureus and Pseudomonas aeruginosa in MHB, serum and vary-
ing proportions of serum admixed with MHB. Slower logarith-
mic growth was obtained for both species in serum compared
to broth, and this might be expected to provide more rapid kill
in serum for a given drug concentration, because of a smaller
microbial challenge. Studies in our laboratory have also estab-
lished slower growth rates in pig serum compared to broth for
P. multocida and A. pleuropneumoniae (L. Dorey and P. Lees,
unpublished data).
For P. multocida, the present findings, of low potency in
serum relative to achievable plasma concentrations, suggest
the possibility of mechanisms of action of oxytetracycline other
than direct killing. The parent drug of this group, tetracycline,
alters the expression of proteins in M. haemolytica at concen-
trations less than MIC (Nanduri et al., 2005). Altered expres-
sion of proteins involved in energy production, nucleotide
metabolism and translation, and the bacterial stress response
(chaperones) were reported. These authors also described a
decrease in the expression of leukotoxin A, a major virulence
factor of M. haemolytica. Another potential action of tetracycli-
nes is on organism pathogenicity, for example by inhibition of
bacterial adherence to cells (Forestier et al., 1984; Gabler et al.,
1992) including epithelial lining cells in the respiratory tract
(Tylewska et al., 1981; Lantz et al., 1987; Haig, 2011).
In addition to these several possible actions of tetracyclines
on bacteria, modification of several functions of mammalian
cells has been reported (Griffin et al., 2011). These include
inhibition of cytokine release (Shapira et al., 1998),
immunomodulation and anti-inflammatory actions (Woo et al.,
1999; Pasquale & Tan, 2005), scavenging of reactive oxygen
moieties (Griffin et al., 2011), induction of nitric oxide syn-
thases (Amin et al., 1996), inhibition of proliferation, migra-
tion and phagocytosis and also induction of apoptosis by
macrophages and antiprotease activity (Fife et al., 1997; Hoe-
ben et al., 1997; Bettany & Wolowacz, 1998; Griffin et al.,
2011). Hence, the clinical response to oxytetracycline might
involve many factors. These include the following: bacterial
species and strain MIC and MBC values; inhibitory effects on
bacteria at sub-MIC concentrations; effects on organism
pathogenicity; disease severity and pathogen load; early
© 2017 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd.
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therapeutic intervention; host immunocompetence and interac-
tion of oxytetracycline with one or several of these factors.
The influence of growth medium on MIC, MBC and MPC
may be attributable to several factors, including protein bind-
ing in serum and other differences in media composition. The
degree of protein binding of oxytetracycline in pig serum was
71%, and it should be noted that protein bound antimicrobial
drugs are antimicrobiologically inactive (Merrikin et al., 1983;
Wise, 1986; Zeitlinger et al., 2004). This value is similar to the
75.5% binding for oxytetracycline reported in piglets (Mevius
et al., 1986) and 72% reported in cattle (Mitchell et al., 2012).
In other cattle studies, however, lower protein binding of
oxytetracycline of 53, 50 and 18.6% has been reported, respec-
tively, by Lees et al. (2015), Pilloud (1973) and Ziv and Sul-
man (1972).
For A. pleuropneumoniae, when correction was made for 71%
protein binding, the fu serum MIC was 4.1-fold lower than the
broth MIC. Therefore, the fu serum:broth ratio of 0.24:1 was
significantly less than the 1:1 ratio anticipated on the assump-
tion (made by most investigators) that there are no differences
between serum and broth, once correction for serum protein
binding has been made. Taking broth MIC as the universally
accepted standard (and noting that in this study it is based on
five overlapping sets of twofold dilutions), our data indicate
that there are serum factor(s) which synergize with oxytetracy-
cline to enhance its killing action against A. pleuropneumoniae.
In confirmation of the serum/broth differences in growth
inhibition for A. pleuropneumoniae, it should be noted that the
‘synergism factor’ for MPC was 4.3, which is almost identical
to the 4.1 factor for MIC. The factor for MBC was somewhat
lower at 2.8. Enhancement of the action of oxytetracycline
might simply be due to a slower rate of logarithmic growth of
A. pleuropneumoniae in serum compared to broth (Dorey et al.
to be published). However, elucidation of the mechanism(s) will
require further study, possibly by comparison against other
slow growing organisms including Mycoplasma spp.
For six bovine isolates of M. haemolytica and P. multocida,
MIC CV% values of 84 and 38%, respectively, were reported
for oxytetracycline (Lees et al., 2016). Similarly the CV% of
P. multocida was small in this study which was 41% for broth
MICs and 21% for serum. For A. pleuropneumoniae, small inter-
isolate variability of MICs with a CV% 12% for broth and 8%
for serum.
In time–kill studies, the killing action of oxytetracycline was
classified as codependent in both broth and serum for both
A. pleuropneumoniae and P. multocida. A conclusion of codepen-
dency was reached in other studies for P. multocida and
M. haemolytica isolates harvested from calves (Brentnall et al.,
2012; Lees et al., 2016). However, other authors have pro-
posed that oxytetracycline action is time-dependent (Mitchell
et al., 2012; Rigos & Smith, 2015).
In this study, a high inoculum count was selected for use in
the time–kill studies. The starting count (approximately
107 CFU/mL) is higher than that recommended by CLSI
(2008) of 5 9 105 CFU/mL and was selected specifically to
provide a major challenge to the killing action of
oxytetracycline. Moreover, our additional data indicate signifi-
cant increases in MIC between low and high and between
medium and high starting inoculum counts; the findings there-
fore anticipate, unsurprisingly, a requirement for higher
dosages for heavy infections in clinical use for both pathogens.
The quantitative differences obtained in this study will provide
a basis for calculating differential doses for differing pathogen
loads and for each pathogenic species.
In the light of the potency indices of oxytetracycline in pig
serum for A. pleuropneumoniae and P. multocida, and from
knowledge of plasma concentrations achieved with clinical
dosages (Mevius et al., 1986), it is clear that (i) concentrations
exceeding the MPC will not be achieved in vivo for either patho-
gen; (ii) microbiologically effective concentrations will probably
be obtained (for a duration to be determined and depending on
pathogen load) for A. pleuropneumoniae but possibly not for
P. multocida. These considerations are further reviewed in a
companion paper to the present article (Dorey et al., 2016).
CONCLUSIONS
In summary, matrix-dependent effects on quantitative MIC,
MBC and MPC values were obtained for oxytetracycline.
Serum:broth ratios were bacterial species dependent for A. pleu-
ropneumoniae and P. multocida; differences were evident after
correction for binding to serum protein for all three indices of
potency, indicating that correction for protein binding (whilst
necessary) is not sufficient to account for matrix potency differ-
ences. Time–kill data demonstrated codependency of killing
action for both A. pleuropneumoniae and P. multocida in both
media. It is concluded that the in vitro potency of oxytetracy-
cline is likely to be better indicated by serum than by broth
MICs. Differences between broth and serum will have implica-
tions for optimization of dosage schedules. Future studies
should integrate and model pharmacokinetic data with phar-
macodynamic indices generated in serum to determine optimal
dosing, for confirmation (or not) in clinical studies.
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